1: Episode I: Allan Gobbs, ATEM Capital

Venture Vitals by Caelestinus

In this compelling episode of Venture Vitals, Tomas and Evgeny sit down with Allan Gobbs, Managing Partner at NY-based Life Sciences venture firm ATEM Capital, to uncover the secrets of health tech investment success. Join us as Allan shares his extraordinary journey from managing a $760M partnership to celebrating multiple NASDAQ listings and high-profile exits.
• Allan’s path to becoming a venture capital virtuoso in digital health.
• Essential advice for aspiring venture capitalists aiming to break into the industry.
• Key components of a successful startup pitch to secure investment from ATEM Capital.
• Insights into Allan’s preferred investment stages and strategies for startups.
• Distinctions between investing in digital health versus other tech sectors.
• Allan’s most triumphant investment stories and the journeys to successful exits.
• Predictions on the next big revolution in digital health.
• Crucial advice for health tech founders and investors.
Allan Gobbs
Allan Gobbs is a Managing Partner at NY-based Life Sciences venture firm ATEM Capital. Prior to ATEM he managed a $760M partnership with Domain Associates. Over the last few years Allan had 5 of his portfolio companies listed on NASDAQ, notably Atea Pharmaceuticals, which yielded a 30x return at IPO, Marinus and Syndax. Four of his portfolio companies have been sold, including Tobira Therapeutics, which was acquired by Allergan at a record 19x premium. Before ATEM Capital, Gobbs was a VP at Barclays Capital and Dresdner Kleinwort, where he advised on M&A and capital market transactions exceeding $20B. Allan is a member of the Forbes Business Council, the Private Directors Association, and the Review Committee of the National Cancer Institute at NIH. More info via https://atemcap.com/